Latest news with #Krabbe
Hamilton Spectator
2 days ago
- Business
- Hamilton Spectator
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Collaboration will leverage Key2Brain's technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated in 2022, supporting continued development led by positive in vivo proof-of-concept data demonstrating the potential of Key2Brain's technology PARMA, Italy and STOCKHOLM, June 11, 2025 (GLOBE NEWSWIRE) — Chiesi Group and Key2Brain today announced a worldwide license agreement to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system. The agreement also includes a framework for the parties to include additional enzymes into the collaboration, enabling the expansion of Chiesi's BBB-crossing ERT portfolio and further strengthening its development capabilities. The advancement of these programs will also contribute to Key2Brain's goal of establishing its technology as a leading BBB-crossing platform. At Chiesi Group, these programs are spearheaded by Chiesi Global Rare Diseases, the Group's dedicated business unit focused on research, development, and commercialization of therapies for rare and ultra-rare conditions. 'At Chiesi Global Rare Diseases, we are deeply committed to building a sustainable pipeline in rare diseases by embracing emerging technologies that can enhance the treatment landscape,' said Giacomo Chiesi, Executive Vice President, Chiesi Global Rare Diseases. 'This agreement exemplifies that vision— working to address areas of profound unmet medical need, including neurodegenerative manifestations of ultra-rare diseases like alpha-mannosidosis and Krabbe disease. For too many families, there are still no therapeutic options. Our goal is to bring them hope.' Under the terms of the agreement, Key2Brain will provide Chiesi Group with a worldwide, royalty- bearing license to develop and commercialize two BBB-crossing ERTs. This agreement is built on an existing research collaboration that aimed to develop the production of a BBB-crossing recombinant alpha-mannosidase. Key2Brain will receive an upfront payment and is eligible to receive development and sales-based milestone payments and tiered royalties on potential sales. Chiesi Group will fund all research, development, and subsequent commercialization worldwide. As part of this agreement, there is also a possibility, upon mutual agreement, for the parties to expand the license to Key2Brain's BBB-crossing technology platform for the development of additional BBB-crossing ERTs. 'This exciting collaboration continuation with Key2Brain represents a strategic opportunity to build on the progress we've already made together,' said Mitch Goldman, Senior Vice President R&D, Chiesi Global Rare Diseases. 'By combining our deep therapeutic expertise with Key2Brain's proprietary BBB-crossing platform technology, we aim to enhance the biodistribution, efficacy and tolerability of promising therapies that have historically faced challenges reaching the central nervous system. Together, our goal is to unlock new therapeutic pathways for patients with lysosomal storage disorders, ultimately delivering meaningful and lasting innovation.' Elisabet Sjöström, Ph.D., Founder and CEO, Key2Brain, said, 'Expanding our relationship with Chiesi Global Rare Disease allows us to build on a clinically validated foundation to address the neurological complications of lysosomal storage disorders, including alpha-mannosidosis and Krabbe disease. Through this agreement, we aim to accelerate the research of potential breakthrough therapies that address these neurodegenerative conditions. We believe this partnership serves as a testament to the versatility and competitiveness of our BBB-crossing technology, unique features that are being utilized in Key2Brain's development of our proprietary next-generation brain-targeting therapies.' This collaboration leverages Key2Brain's proprietary BBB-crossing platform technology and Chiesi Global Rare Diseases' capabilities and expertise in this ultra-rare disease landscape, creating a path to advance the ongoing aMann-K2B program as well as initiate new preclinical programs that apply Key2Brain's technology to other LSDs. About Chiesi Group Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For more information visit: About Chiesi Global Rare Diseases Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit: . Follow @ChiesiGlobalRareDiseases on LinkedIn, Facebook, Instagram, X and YouTube. About Key2Brain Key2Brain is a Swedish biotechnology company dedicated to developing next generation brain targeting therapeutics utilizing its proprietary blood-brain barrier-crossing (BBB-crossing) technology. The technology enables efficient brain uptake and broad distribution of CNS-therapeutics, utilizing small and flexible antibody fragments (VHHs). Key2Brain's VHHs can be integrated into a wide range of therapeutic molecules. The pipeline is being developed internally and in partnerships where Key2Brain's team leverages extensive industry experience in biologics and brain-targeting drugs, accelerating the translation from discovery to the clinic. Key2Brain was founded 2020 and is based in Stockholm. For more information visit: About Key2Brain's technology platform Key2Brain's technology enables efficient brain uptake and broad distribution of therapeutics, utilizing small (<15kDa) engineered single domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR). The technology provides opportunities for the development of next generation brain targeting across a diverse range of therapeutic areas. Key2Brain's VHH technology can be efficiently integrated into or combined with therapeutic molecules without impacting either the disease target specificity, or the binding of transferrin to TfR. The modular and flexible platform is being applied to peptides, proteins, enzymes, and oligonucleotides. Key2Brain's VHHs can be expressed in both prokaryotic and eukaryotic systems and purified using commercial large-scale affinity purification systems. The proprietary platform includes species cross-reactive (human/primate/mouse) as well as human/primate specific binders together with a humanized TfR mouse model for translational studies. Chiesi Global Rare Diseases Media Contact Sky Striar LifeSci Communications sstriar@ Key2Brain Media Contact Benjamin Nordin, CBO Key2Brain
Associated Press
08-04-2025
- Health
- Associated Press
From Pain to Power: Emotional Transformation Movement Announced by Salvia para el Alma Founder Yuni Krabbe
Founder Yuni Krabbe launches a transformative soul-healing movement rooted in ancestral energy, emotional liberation, and spiritual alignment. United States, April 8, 2025 -- The Path of Awakening: Salvia para el Alma's Mission in Motion In a world grappling with emotional burnout and spiritual disconnection, transformational energy healer and Founder of Salvia para el Alma, Yuni Krabbe, has emerged as a powerful guide leading thousands toward deeper healing and alignment. Through a soul-led fusion of ancestral medicine, Kundalini energy activation, Reiki, and holistic wellness therapies, Krabbe's unique approach offers what many are calling 'soul alchemy'—a complete energetic rebirth that reconnects people to their inner truth. With a growing presence across sacred retreats, healing ceremonies, and one-on-one transformation journeys, Krabbe's brand isn't just offering services—it's awakening a movement. Rooted in authenticity and spiritual integrity, her work addresses the core emotional wounds that keep people disconnected from their purpose. For Krabbe, the soul is the compass—and healing is the key that unlocks its direction. Beyond Healing: A Sacred Container for Soul-Led Leadership Krabbe's mission is distinct: not just to help others feel better, but to activate their truest self. 'What sets me apart is the depth of transformation I offer,' she says. 'I don't do surface-level healing—I go to the root.' Salvia para el Alma is designed to be a sacred energetic space where individuals feel safe enough to break down, release, and reconstruct themselves from a higher frequency. Her work extends beyond physical or emotional recovery—it is a rite of passage into personal power, divine remembrance, and spiritual sovereignty. The results are tangible: clients report emotional breakthroughs, energetic recalibrations, and a renewed sense of purpose. 'True healing begins when we stop running from our pain and start listening to its wisdom. That's where freedom lives,' Krabbe says. Emotional Liberation as the Gateway to Abundance and Purpose At the heart of Krabbe's work is a simple yet revolutionary truth: emotional liberation is the bridge to all forms of abundance. By unblocking trapped emotions and releasing ancestral patterns, individuals create space for clarity, creativity, and aligned success. 'Our emotional wounds aren't blocks—they're invitations. They hold the wisdom we need to move forward, but only if we're willing to listen,' Krabbe explains. Her holistic methods combine deep energetic release with modern somatic techniques, allowing clients to reset not only their mindset but their entire energetic frequency. This inner work has catalyzed life changes for clients across the globe—shifts in relationships, careers, and self-worth that ripple outward into families, communities, and beyond. Global Impact Rooted in Ancient Wisdom Krabbe's approach blends timeless spiritual principles with today's need for embodied leadership and collective healing. Each experience she facilitates is crafted with intention and reverence for the sacred. Whether guiding Kundalini activations, holding space in a ceremony, or mentoring private clients, she leads with a grounded presence and a powerful energetic signature. The impact of Salvia para el Alma is already extending beyond borders. Krabbe has facilitated international retreats and continues to draw clients from diverse cultural and spiritual backgrounds seeking deep, authentic transformation. Her vision is global, yet her work remains deeply personal. 'I'm here to ignite the fire within—the leader, the healer, the soul that's been waiting to rise,' she shares. 'This isn't just about wellness. It's about soul revolution.' A Movement for the Modern Age: Why Salvia para el Alma Stands Out In a wellness space often filled with trend cycles and surface-level inspiration, Salvia para el Alma's depth offers a refreshing alternative. Krabbe's unique gift lies in how she merges ancient modalities with the present moment's spiritual needs. Her offerings are not one-size-fits-all. Each experience is intuitively guided, energetically tailored, and rooted in the sacred. Clients often describe sessions with her as life-altering—emerging with a new sense of clarity, sovereignty, and spiritual embodiment. This energetic integrity, paired with her heart-led leadership, sets Krabbe apart. 'My presence is my power, and my work is a transmission,' she states. Future Vision: Expanding the Sacred Mission Looking ahead, Krabbe is focused on expanding the reach of her transformational work across new digital platforms, global collaborations, and soul-centered partnerships. Her goal is to bring emotional healing and energetic awakening into the mainstream conversation, particularly in leadership, wellness, and creative industries. While remaining true to the spiritual roots of her work, Krabbe is open to aligned opportunities that allow her mission to scale—without compromising the sacred nature of the journey. 'I'm fully committed to expanding this movement worldwide,' she says. 'And I'm calling in those who are ready to co-create from a place of truth, love, and spiritual purpose.' About Salvia para el Alma Salvia para el Alma is a transformational healing brand founded by Yuni Krabbe, a trauma specialist and energy healer. Rooted in ancient spiritual practices and modern energy modalities, the brand offers deep emotional release, soul awakening, and holistic alignment through personalized sessions, retreats, and sacred ceremonies. The mission is to help individuals remember who they are, rise into their truth, and activate the power within. Media Contact Yuni Krabbe Founder, Salvia para el Alma Email: [email protected] Website: Instagram: @ Contact Info: Name: Yuni Krabbe Email: Send Email Organization: Salvia para el Alma Release ID: 89157081 If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
Yahoo
12-02-2025
- Health
- Yahoo
8-year-old in Stokes County fights rare brain disease
WALNUT COVE, N.C. (WGHP) — To know Bentley Shelton is to love him. 'He brings light to everybody that meets him,' said Brittany Shelton, Bentley's mom. 'He always smiles.' At 8 years old, Bentley faces more challenges than most kids his age. But it wasn't always that way. Parents of separated conjoined twin daughters rely on faith after son's pediatric cancer diagnosis 'He was born like a normal kid. He started walking at age one,' said Shelton. 'For a year, he climbed on top of things, he'd climb up on tables and everything. And then he just kind of started being clumsy and when I went back and looked at videos, and I knew what to look for I noticed signs; his knees would hyperextend, his ankles were not 90 degrees, and it was causing him to just not walk properly. Six weeks after those initial signs showed up, Bentley was diagnosed with Krabbe Leukodystrophy, a rare genetic disorder that causes progressive damage to the nervous system. Bentley is one of nearly 30 million Americans who live with a rare disease. 'He has to fight really hard to maintain what he has,' said Shelton. 'Every day is a constant struggle.' There is no cure for Krabbe, and treatment is limited to a stem cell transfer which Bentley underwent in Pittsburgh right after he was diagnosed. High Point teen undergoes special surgery with determination, a smile 'He has essentially lost his ability to walk. He loves to try so we help him, but he can't do it unassisted,' said Brittany. 'It did affect his vision. He was diagnosed with cortical visual impairment which I've kind of understood to be your eyes work fine, but your pathway doesn't. So, he looks at something and he can't process it… everything is just jumbled.' In late January, the Shelton family received another blow. A promising clinical trial involving gene therapy that Bentley was waitlisted for was abruptly canceled. Brittany turned to Facebook to share the devastating news. 'I think the more noise you make, the more people become aware,' said Brittany. 'That's really the only thing you can do.' Her post has been shared hundreds of times, and she's heard from people who work with pharmaceutical companies offering advice. 'I was just praying that someone would see it… that a pharmaceutical company would see it and take interest and see that these are real kids out there that have it and hopefully pick it back up and restart it.' It feels like a relentless race against time that Shelton is determined to help Bentley win. Micro-preemie twins born in Triad beat the odds, set to come home from hospital 'Science tells us you don't live a full life, but you know God tells us another thing, so we're hoping and praying for other treatments to become available,' said Shelton. 'It's a rare disease but it's one in 100-thousand and when you compare that to the whole population, that's a lot of kids. That's brothers, sisters, sons and daughters.' The Krabbe Disease clinical program by Forge Biologics was scheduled to run until November 2026. FOX8 reached out to Forge Biologics to find out what led to the program's cancellation, but we haven't heard back. Krabbe disease is not on the newborn screen in North Carolina. It is, however, part of newborn screenings in several other states including South Carolina and Tennessee. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
